$17M Series A Financing towards Ataxias Drug Development

Cambridge, MA-based Ataxion has secured $17M in series A financing from Biogen Idec and Atlas Venture. This new startup biotech company is focused on rare neurodegenerative diseases called orphan hereditary ataxias, a group of hereditary disorders associated with loss of motor coordination due to degeneration of Purkinje cells in the cerebellum (see related story from January 2013). Ataxion’s therapeutic approach aims to alleviate the symptoms of the disease by normalizing firing patterns of Purkinje cells, rather than providing a genetic or protein-based cure. Interestingly, a genetic link between ataxias and ALS has been found in form of the ataxin-2 gene (see story from August 2013).

Cambridge, MA-based Ataxion has secured $17M in series A financing from Biogen Idec and Atlas Venture. This new startup biotech company is focused on rare neurodegenerative diseases called orphan hereditary ataxias, a group of hereditary disorders associated with loss of motor coordination due to degeneration of Purkinje cells in the cerebellum (see related story from January 2013). Ataxion’s therapeutic approach aims to alleviate the symptoms of the disease by normalizing firing patterns of Purkinje cells, rather than providing a genetic or protein-based cure. Interestingly, a genetic link between ataxias and ALS has been found in form of the ataxin-2 gene (see story from August 2013).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail